4-(AMINOMETHYL)BENZENESULFONAMIDE ACETATE; Mafatate; Mafenamide acetate; Maphenide acetate; Mafenide (Acetate); UNII-RQ6LP6Z0WY; Benzenesulfonamide, 4-(aminomethyl)-, monoacetate; p-Aminomethylbenzenesulfonamide acetate; alpha-Amino-p-toluenesulfonamide monoacetate; 4-(Aminomethyl)benzenesulfonamide monoacetate; alpha-Aminotoluene-4-sulphonamide monoacetate; RQ6LP6Z0WY; acetic acid;4-(aminomethyl)benzenesulfonamide; MFCD00072089; Winthrocine; Sulfamilon; Benzenesulfonamide, 4-(aminomethyl)-, acetate (1:1); 4-(aminomethyl)benzenesulfonamide, acetic acid; EINECS 235-855-0; Mafenide acetate [USP:JAN]; Sulfamylon (TN); 4-(Aminomethyl)Benzenesulfonimideacetate; p-Toluenesulfonamide, alpha-amino-, monoacetate; SCHEMBL41627; Mafenide acetate (JAN/USP); MLS000069581; ARONIS24094; CHEMBL1201161; CTK8B5794; HY-B0614A; KS-00000GIF; DTXSID00156334; HMS2231M06; HMS3259N08; HMS3370M14; BCP28537; EBD47349; ANW-50131; s3647; SBB080601; AKOS000121908; AT-3012; CCG-266920; DS-2178; MP-0204; NC00709; KS-000046K4; AC-22835; AK-33093; SC-17842; SMR000058778; 4-(Aminomethyl)benzenesulfonamide (acetate); 4-Aminomethylbenzenesulfonamide acetate salt; AB0015310; DB-041939; AM20050421; FT-0630395; ST45053309; D01166; 4-(aminomethyl)benzene-1-sulfonamide; acetic acid; W-108356; Q27288250; Mafenide Acetate; 4-(aminomethyl)-benzenesulfoamide monoacetate; Mafenide acetate, United States Pharmacopeia (USP) Reference Standard